Securities Industry Begins Halting Sales of Funds Including Osstem Implant

[Asia Economy Reporter Park Jihwan] The securities industry has halted sales of funds containing Ostem Implant following the suspension of trading due to an employee embezzlement case involving 188 billion KRW.

On the afternoon of the 6th, Daishin Securities announced through a notice that it would stop new purchases of 63 funds containing Ostem Implant, including the KB Value Focus 30 Securities Investment Trust (Bond Mixed), to protect customers' profits. Daishin Securities explained, "These funds reflect the closing price of Ostem Implant stock at the end of last year as the base price, so there is a possibility of a decline in the base price when trading resumes." However, additional payments and automatic transfers are still possible, but investors are advised to consider this information when making investment decisions.

Mirae Asset Securities also announced on the same day that it would suspend sales of funds containing Ostem Implant. There are 106 domestic funds containing Ostem Implant, and the ETF 'Mirae Asset TIGER Medical Devices' has 7.7% of its total assets invested in Ostem Implant.

Mirae Asset Global Investments stated, "Index funds such as ETFs cannot arbitrarily exclude stocks as it would cause tracking errors with the benchmark index, so changes will follow the benchmark index adjustments. Active funds will decide on holding or selling based on the delisting review results and the market price when trading resumes through valuation assessments."

Earlier, Hana Bank also suspended sales of 77 funds containing Ostem Implant on the 5th.

This content was produced with the assistance of AI translation services.